Julian Panes

Julian Panes

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 288 publications

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Journal: Inflammatory bowel diseases

Published: December 18, 2025

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

Journal: The American journal of gastroenterology

Published: October 15, 2025

Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.

Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 08, 2025

Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.

Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: July 04, 2025

TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.

TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.

Journal: Gut

Published: June 30, 2025

Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.

Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.

Journal: Journal of Crohn's & colitis

Published: June 09, 2025

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients.

Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients.

Journal: Journal of Crohn's & colitis

Published: May 05, 2025

An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease.

An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease.

Journal: EClinicalMedicine

Published: April 22, 2025

Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis.

Definitions, diagnosis, and management of postoperative recurrence in Crohn's disease patients with permanent ileostomy-a systematic review and meta-analysis.

Journal: Journal of Crohn's & colitis

Published: March 11, 2025

Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.

Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.

Journal: Gastroenterology

Published: January 27, 2025

Treatment patterns and outcomes of patients with complex Crohn's perianal fistula in five European countries: the PREFACE study.

Treatment patterns and outcomes of patients with complex Crohn's perianal fistula in five European countries: the PREFACE study.

Journal: Acta gastro-enterologica Belgica

Published: January 02, 2025

Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.

Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.

Journal: Lancet (London, England)

Published: December 20, 2024

Showing 1-12 of 288

Last Updated: 09/26/2026